New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunov...
April 16 2018 - 9:05AM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced that it presented new
research on its T-cell activating platform at the American
Association for Cancer Research (AACR) Annual Meeting 2018.
In collaboration with Incyte Corporation, researchers presented
a poster supporting the enhanced anti-cancer immune responses from
the combination of Immunovaccine’s proprietary T cell activating
technology and Incyte’s IDO1 inhibitor program. A second poster
analyzed the novel capability, as compared to other formulation
technologies, of Immunovaccine’s delivery technology to combine a
large range of anti-cancer peptides into a single formulation.
“This is important data for our Company as it further indicates
the potential of our collaborative work, including our ongoing
program with Incyte, to provide heightened T cell infiltration and
overall anti-cancer immune responses,” said Frederic Ors, Chief
Executive Officer, Immunovaccine. “Our data at AACR continues to
demonstrate that our novel mechanism of action may hold the key to
bridging the gap between in vivo therapies that can elicit T cell
activation, and immune responses that can trigger disease
regression. We look forward to continued work on these important
programs.”
In the poster, “Combination of a T cell activating immunotherapy
with immune modulators alters the tumour microenvironment and
promotes more effective tumour control in preclinical models,”
researchers presented new preclinical analysis on the combination
of Immunovaccine’s DPX-based therapies, Incyte’s epacadostat, and
low-dose cyclophosphamide in tumor models. As part of the analysis,
researchers also examined the potential for heightened tumor
response from T cell infiltration in the tumour microenvironment.
The study indicated that the triple combination immunotherapy
demonstrated a significant delay in tumour progression. Analysis of
the T cells suggested that other immune modulating therapies, such
as checkpoint inhibitors, could further enhance tumour control.
Related to Immunovaccine’s neoepitope program, researchers
presented the poster, “A novel delivery platform containing up to
25 neoantigens can induce robust immune responses in a single
formulation.” This study investigated the effects on immune
response when formulating a broad range of peptides across multiple
delivery technologies, including the Company’s proprietary
formulation. The study indicated that Immunovaccine’s novel
technology could incorporate at least 25 neo-antigens into a single
formulation, which generated strong CD8+ T cell responses, in
excess of those induced by other formulations.
About Immunovaccine Immunovaccine
Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. Immunovaccine develops T cell-activating cancer
immunotherapies based on the Company’s proprietary drug delivery
platform. This patented technology provides controlled and
prolonged exposure to a broad range of immunogenic stimuli.
Immunovaccine has advanced two T cell-activating therapies for
cancer through Phase 1 human clinical trials and is currently
conducting a Phase 1b study with Incyte Corporation assessing its
lead cancer therapy, DPX-Survivac, as a combination therapy in
ovarian cancer. The Company is also exploring additional
applications of its platform, including DPX-RSV, an innovative
vaccine candidate for respiratory syncytial virus (RSV), which has
recently completed a Phase 1 clinical
trial. Immunovaccine also has ongoing clinical projects
to assess the potential of DepoVax to address malaria and the Zika
virus. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking Statements This
press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of them will be achieved. Actual results
may differ materially from those set forth in this press release
due to risks affecting the Company, including access to capital,
the completion of clinical trials and receipt of all regulatory
approvals. Immunovaccine Inc. assumes no responsibility
to update forward-looking statements in this press release except
as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown Inc. T:
(312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS Pierre Labbé, Chief
Financial Officer T: (902) 492-1819 E: info@imvaccine.com
Patti Bank, Managing Director, Westwicke
Partners O: (415) 513-1284 T: (415) 515-4572
E: patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024